Interface Biologics-BASF Future Business Collaborate
News Jan 05, 2011
By joining IBI's anti-thrombogenic technology with BASF's proprietary anti-microbial technology platform, a combined effect can be achieved that will lead to new materials that can substantially improve the safety and performance of medical devices.
BASF Future Business GmbH opens up new business opportunities for BASF, the chemical industry's leading player. "In the area of medical devices materials we expand our offering by developing enabling solutions for our customers in partnership with highly innovative companies such as Interface Biologics, Inc.", commented Stefan Becker of BASF Future Business GmbH. "We are impressed with IBI's world class technology and are excited to work with their team. New functional materials for medical applications not only improve the standard of medical care for an aging population, but also address important economic needs such as the cost pressure in the healthcare system. Polymeric materials able to prevent dangerous and costly hospital acquired infections are an important example."
Mark Steedman, V.P. Business Development at IBI, underscored the strategic importance of working with BASF Future Business. "This co-development agreement with BASF represents a major milestone for IBI on two fronts. First, in combining our Endexo anti-thrombogenic additives with BASF's proprietary anti-microbial technology, this is the first time that we have investigated a combination effect. If successful, this could open up other opportunities for other combination benefits with the Endexo polymers. Second, to partner with a major industry player like BASF underscores the interest in IBI's technology as a fundamental future building block of new material development. We are excited about this strategic partnership with BASF and look forward to mutually successful product developments".
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019